Intensity Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INTS research report →
Companywww.intensitytherapeutics.com
Intensity Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers.
- CEO
- Lewis H. Bender
- IPO
- 2023
- Employees
- 5
- HQ
- Westport, CT, US
Price Chart
Valuation
- Market Cap
- $8.73M
- P/E
- -10.97
- P/S
- 0.00
- P/B
- 11.76
- EV/EBITDA
- 0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -136.82%
- ROIC
- -110.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,606,000 · 28.66%
- EPS
- $-8.56 · 70.74%
- Op Income
- $-11,972,000
- FCF YoY
- 39.34%
Performance & Tape
- 52W High
- $43.50
- 52W Low
- $4.50
- 50D MA
- $5.61
- 200D MA
- $8.01
- Beta
- 3.26
- Avg Volume
- 34.26K
Get TickerSpark's AI analysis on INTS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 26, 26 | BENDER LEWIS H | other | 37,749 |
| Dec 31, 25 | Wesolowski John M | other | 8,918 |
| Dec 31, 25 | Talamo Joseph | other | 14,482 |
| Jun 30, 25 | Wesolowski John M | other | 69,745 |
| Jun 30, 25 | Talamo Joseph | other | 14,179 |
| May 2, 25 | DUBIN THOMAS I H | other | 50,000 |
| May 2, 25 | Donovan Daniel | other | 50,000 |
| May 2, 25 | GOLDBERG MARK A | other | 50,000 |
| May 2, 25 | Leahy Emer | other | 50,000 |
| May 2, 25 | Wesolowski John M | other | 100,000 |
Our INTS Coverage
We haven't published any research on INTS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INTS Report →